Tozorakimab has met its primary endpoint in two replicate Phase [...]

GSK announced that the European Commission has approved Exdensur (depemokimab) [...]

Full results from the Phase 3 KALOS and LOGOS trials [...]

Cereno Scientific has broadened the clinical development focus of its [...]

Cereno Scientific has published the first peer-reviewed paper describing its [...]

  The National Institute for Health and Care Excellence has [...]

Flagship Pioneering has announced that ProFound Therapeutics and Quotient Therapeutics [...]

Phase 3 data for GSK’s depemokimab appear to support the [...]